Details of Disease

General Information of Disease (ID: DIS2FCCT)

• Disease Name: Diabetic nephropathy
• Disease Class: GB61: Chronic kidney disease
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DIS2FCCT: Diabetic nephropathy
• ICD Code:
  ICD-11: ICD-11: GB61.Z
  ICD-9: ICD-9: 250.4
  Expand ICD-11: 'GB61.Z
  Expand ICD-9: 250.4
• Disease Identifiers:
  MONDO ID: MONDO_0005016
  MESH ID: D003928
  UMLS CUI: C0011881
  MedGen ID: 8352
  SNOMED CT ID: 127013003

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 5 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Canagliflozin	DMFRM1I	Approved	Small molecular drug	[1]
Corticotropin	DMP9TWZ	Approved	NA	[2]
Defibrotide	DM6CWSO	Approved	NA	[3]
Finerenone	DMM4FJ3	Approved	NA	[1]
SM-101	DMFX9O6	Approved (orphan drug)	Small molecular drug	[4]

This Disease is Treated as An Indication in 33 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Atrasentan	DMM74PK	Phase 3	Small molecular drug	[1]
Dimesna	DMU4T9Y	Phase 3	Small molecular drug	[5]
Pyridoxamine	DMVDCGZ	Phase 3	Small molecular drug	[6]
AGN-XX/YY	DMMGAUK	Phase 2	Small molecular drug	[7]
ASP8232	DMYK1JU	Phase 2	NA	[8]
BI 685509	DMIVVON	Phase 2	NA	[9]
BMS-813160	DMKY638	Phase 2	NA	[10]
CCX-140	DMJ9XCO	Phase 2	NA	[11]
CCX872	DMPVAUT	Phase 2	NA	[12]
CTP-499	DMUXLWK	Phase 2	Small molecular drug	[13]
DM199	DM0157T	Phase 2	Recombinant protein	[14]
DW-1029M	DMO0Q2D	Phase 2	NA	[15]
GFB-887	DM2IJWG	Phase 2	Small molecule	[16]
GS-4977	DMBDFN7	Phase 2	NA	[17]
GS-4997	DMNABMU	Phase 2	NA	[18]
LMB763	DMQOXNL	Phase 2	Small molecular drug	[19]
LY2382770	DMH3YKJ	Phase 2	Antibody	[20]
Modified hepatocyte growth factor gene therapy	DM9DJRP	Phase 2	NA	[21]
MPC-300-IV	DMRWDG9	Phase 2	NA	[1]
MT-3995	DMXSZA4	Phase 2	NA	[22]
Nerenone	DMBJ3GL	Phase 2	NA	[23]
Nimacimab	DM21Z68	Phase 2	Antibody	[24]
Ocaperidone	DMP6B59	Phase 2	Small molecular drug	[4]
PF-04634817	DM0GBB5	Phase 2	NA	[25]
PHN-031	DMZBS98	Phase 2	NA	[26]
SAR-407899	DMF95KD	Phase 2	NA	[27]
TMX-049	DME8PFQ	Phase 2	NA	[28]
VPI-2690B	DMUQZT4	Phase 2	NA	[1]
BI 690517	DM3OLD7	Phase 1	NA	[29]
GFB-024	DM0L401	Phase 1	Antibody	[30]
TTPABC	DMZEVJR	Phase 1	NA	[31]
oxazine 89	DMXFI90	Clinical trial	Small molecular drug	[32]
SP 20202	DMOVGXM	Clinical trial	NA	[33]

This Disease is Treated as An Indication in 6 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Ilepatril	DMTR50E	Discontinued in Phase 2/3	NA	[34]
Avosentan	DM2I8NT	Discontinued in Phase 2	Small molecular drug	[35]
NP-1998	DMDAGGR	Discontinued in Phase 2	NA	[36]
XL784	DMICR39	Discontinued in Phase 2	NA	[4]
SAR101099	DMIZ7Q4	Discontinued in Phase 1	NA	[37]
PF-03882845	DMOS9NZ	Terminated	Small molecular drug	[38]

This Disease is Treated as An Indication in 2 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ATL-1222	DMNT8OB	Investigative	NA	[39]
CLT-002	DMAEAL6	Investigative	NA	[39]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] ClinicalTrials.gov (NCT01939132) Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis. U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT00358501) Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients. U.S. National Institutes of Health.
• [4] Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs. 2008 Sep;13(3):447-63.
• [5] BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts. Eur J Cancer. 2002 May;38(8):1148-56.
• [6] ClinicalTrials.gov (NCT02156843) Pyridorin in Diabetic Nephropathy. U.S. National Institutes of Health.
• [7] Clinical pipeline report, company report or official report of ACADIA Pharmaceuticals.
• [8] Clinical pipeline report, company report or official report of Astellas Pharma.
• [9] ClinicalTrials.gov (NCT04750577) A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney Disease. U.S. National Institutes of Health.
• [10] ClinicalTrials.gov (NCT01752985) Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease. U.S. National Institutes of Health.
• [11] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018498)
• [12] ClinicalTrials.gov (NCT02345408) Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma. U.S. National Institutes of Health.
• [13] ClinicalTrials.gov (NCT01487109) A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients. U.S. National Institutes of Health.
• [14] ClinicalTrials.gov (NCT01845064) A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes Patients. U.S. National Institutes of Health.
• [15] ClinicalTrials.gov (NCT01935167) To Determine the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy. U.S. National Institutes of Health.
• [16] ClinicalTrials.gov (NCT04387448) A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease. U.S.National Institutes of Health.
• [17] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040265)
• [18] ClinicalTrials.gov (NCT02234141) GS-4997 in Adults With Pulmonary Arterial Hypertension. U.S. National Institutes of Health.
• [19] ClinicalTrials.gov (NCT03804879) Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy. U.S. National Institutes of Health.
• [20] ClinicalTrials.gov (NCT01113801) A Study in Patients With Diabetic Kidney Disease. U.S. National Institutes of Health.
• [21] ClinicalTrials.gov (NCT01548378) Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia. U.S. National Institutes of Health.
• [22] ClinicalTrials.gov (NCT01756703) A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria. U.S. National Institutes of Health.
• [23] Clinical pipeline report, company report or official report of Bayer HealthCare Pharmaceuticals.
• [24] ClinicalTrials.gov (NCT03900325) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy of Nimacimab in Patients With Diabetic Gastroparesis. U.S. National Institutes of Health.
• [25] ClinicalTrials.gov (NCT01712061) A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy. U.S. National Institutes of Health.
• [26] Product pipeline of PhytoHealth Corporation.
• [27] ClinicalTrials.gov (NCT00914277) SAR407899 Single-dose in Treatment of Mild to Moderate Erectile Dysfunction. U.S. National Institutes of Health.
• [28] ClinicalTrials.gov (NCT03449199) Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria. U.S. National Institutes of Health.
• [29] ClinicalTrials.gov (NCT02891148) Single Rising Dose Study of BI 690517 in Healthy Volunteers. U.S. National Institutes of Health.
• [30] ClinicalTrials.gov (NCT04880291) A First-In-Human, Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GFB-024 as a Single Dose in Healthy Overweight and Obese Participants and as Multiple Doses in Participants With Type 2 Diabetes Mellitus. U.S.National Institutes of Health.
• [31] Biopharmaceutical Research Companies Are Developing More Than 220 Medicines to Treat Diabetes and Related ConditionsPharmaceutical Research and Manufacturers of America report. Pharmaceutical Research and Manufacturers of America report. 2012.
• [32] beta-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease. J Med Chem. 2013 May 23;56(10):3980-95.
• [33] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
• [34] Ilepatril (AVE-7688), a vasopeptidase inhibitor for the treatment of hypertension. Curr Opin Investig Drugs. 2008 Mar;9(3):301-9.
• [35] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8260).
• [36] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026942)
• [37] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033702)
• [38] Clinical pipeline report, company report or official report of Pfizer (2011).
• [39] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [40] Therapeutic approaches to diabetic nephropathy--beyond the RAS. Nat Rev Nephrol. 2014 Jun;10(6):325-46.